Drilldown: Medicines

None (1) · Allopurinol (1)

Caplyta (1) · Zyloprim, Aloprim (IV) (1)

5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity (1) · Atypical antipsychotic (1) · [[:Category:Antigout_agents|Antigout agent]] (1) · [[:Category:Antihyperuricemic_agents|Antihyperuricemic agent]] (1) · [[:Category:Xanthine_oxidase_inhibitors|Xanthine oxidase inhibitor]] (1)

None (2)

Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1) · '"`UNIQ--vote-0000030B-QINU`"', '"`UNIQ--vote-0000030C-QINU`"', '"`UNIQ--vote-0000030D-QINU`"', '"`UNIQ--vote-0000030E-QINU`"' (1)

100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease) (1) · 42 mg PO once daily with food (no titration) (1)

100 mg, 300 mg tablets; IV 500 mg vial (1) · 42 mg capsules (1)

42 mg/d (1) · 800 mg/d (rarely needed) (1)

IV (1) · Oral (2)

Antipsychotic effect over weeks (1) · Serum urate falls gradually over days to weeks; acute flare prevention requires colchicine cover during initiation (1)

24 hours (1) · Daily dosing (1)

None · ~12 hours · ~27 days · ~5 h (caffeine) · '''Autoinduction''': 25-65 hours initially, falling to 12-17 hours after 2-3 weeks of dosing as carbamazepine induces its own CYP3A4 metabolism. Major clinical implication: doses require re-titration after the autoinduction period'"`UNIQ--ref-0000001D-QINU`"' · 0.5-1.5 hours (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-000000DE-QINU`"' · 1-1.3 hours'"`UNIQ--ref-000001A1-QINU`"' · 1-1.5 hours'"`UNIQ--ref-00000DE3-QINU`"' · 1-2 hours (parent compound)'"`UNIQ--ref-00000029-QINU`"' · 1-2 hours (parent); 18-30 hours for active metabolite oxypurinol'"`UNIQ--ref-0000030F-QINU`"' · 1-2 hours'"`UNIQ--ref-00000017-QINU`"' · 1-3 days acute, 4-6 days chronic; 4-16 days for norfluoxetine'"`UNIQ--ref-0000004C-QINU`"' · 1-3 hours (normal liver); markedly prolonged in overdose with glutathione depletion'"`UNIQ--ref-00000022-QINU`"' · 1-3 minutes (very short)'"`UNIQ--ref-00000C0F-QINU`"' · 1.4 hours (parent); 13-24 hours for active metabolite canrenone'"`UNIQ--ref-00000354-QINU`"' · 1.5-2 hours (longer in renal failure)'"`UNIQ--ref-00000222-QINU`"' · 1.5-2 hours'"`UNIQ--ref-00000020-QINU`"' · 10-11 hours (benazeprilat, the active metabolite)'"`UNIQ--ref-00000A22-QINU`"' · 11-13 h (immediate-release); 11-16 h (extended-release) · 11-15 hours'"`UNIQ--ref-00000842-QINU`"'

Other values:

Search

Limited but adequate; take with food (1) · ~80% (oral)'"`UNIQ--ref-00000310-QINU`"' (1)

Limited data; National Pregnancy Registry for Atypical Antipsychotics (1) · Limited safety data; weigh benefit individually.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

Rx (1) · [[USLegal:Prescription only|Rx-only]] in US (1)